We are live on ! Find out more
ANIX icon

Anixa Biosciences

35 hedge funds and large institutions have $15.2M invested in Anixa Biosciences in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

32% more capital invested

Capital invested by funds: $11.5M → $15.2M (+$3.7M)

9% more funds holding

Funds holding: 3235 (+3)

0.75% more ownership

Funds ownership: 9.86%10.61% (+0.75%)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

21% less call options, than puts

Call options by funds: $251K | Put options by funds: $317K

Holders
35
Holders Change
+3
Holders Change %
+9.38%
% of All Funds
0.61%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
8
Reduced
10
Closed
4
Calls
$251K
Puts
$317K
Net Calls
-$66K
Net Calls Change
-$125K

ANIX Hedge Fund Activity: Q3 2021 in Review

35 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q3 2021, worth a combined $15.2M — up 32% from $11.5M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ANIX positions and 4 closed out — a net gain of 3 holders — while 8 added to existing stakes and 10 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $396K. The largest seller was UBS Group, cutting an estimated $473K.

  • 35 institutional investors held Anixa Biosciences (ANIX) as of Q3 2021, up from 32 in Q2 2021.
  • Funds reported $15.2M of Anixa Biosciences stock for Q3 2021, up 32% quarter-over-quarter.
  • 7 funds opened new Anixa Biosciences positions in Q3 2021 and 4 closed out, a net change of +3 holders.
  • The largest Anixa Biosciences buyer in Q3 2021 was Renaissance Technologies, an estimated $396K added.
  • The largest Anixa Biosciences seller in Q3 2021 was UBS Group, an estimated $473K sold.

Based on aggregated 13F filings for Q3 2021.